ΠΠ½ΡΡΠ°ΡΠΏΠΈΡΠ΅Π»ΠΈΠ°Π»ΡΠ½Π°Ρ Π½Π΅ΠΎΠΏΠ»Π°Π·ΠΈΡ ΠΌΠΎΠ»ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ
ΠΠ΅ΡΠΊΠΎΠ»ΡΠΊΠΎ Π΄Π΅ΡΡΡΠΈΠ»Π΅ΡΠΈΠΉ Π½Π°Π·Π°Π΄ CIS Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΡΠΎΠ²Π°Π»ΠΈ ΡΠΎΠ»ΡΠΊΠΎ Π² 3β5% ΡΠ»ΡΡΠ°Π΅Π² ΠΎΡ Π²ΡΠ΅Ρ Π²Π½ΠΎΠ²Ρ Π²ΡΡΠ²Π»ΡΠ΅ΠΌΡΡ Π ΠΠ. ΠΠ°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠ΅ Π²ΡΡΠ²Π»ΡΠ»ΠΎΡΡ ΡΠ»ΡΡΠ°ΠΉΠ½ΠΎ ΠΏΡΠΈ ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΌ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΈ ΠΏΠΎΡΠ»Π΅ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΎΠ½Π½ΠΎΠ³ΠΎ ΠΌΠ°ΡΠ΅ΡΠΈΠ°Π»Π° Π½Π° ΡΠΎΠ½Π΅ ΠΌΠ°ΡΡΠΎΠΏΠ°ΡΠΈΠΈ ΠΈΠ»ΠΈ ΠΊΠ°ΠΊ ΡΠΎΡΡΠ°Π²Π½Π°Ρ ΡΠ°ΡΡΡ ΠΈΠ½Π²Π°Π·ΠΈΠ²Π½ΠΎΠΉ ΠΊΠ°ΡΡΠΈΠ½ΠΎΠΌΡ. ΠΠ»Π°Π³ΠΎΠ΄Π°ΡΡ ΡΠ°Π·Π²ΠΈΡΠΈΡ ΠΌΠ°ΠΌΠΌΠΎΠ³ΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠ΅Ρ Π½ΠΈΠΊΠΈ ΠΈ Π²Π½Π΅Π΄ΡΠ΅Π½ΠΈΡ ΡΠΊΡΠΈΠ½ΠΈΠ½Π³Π° ΡΠ°ΡΡΠΎΡΠ° Π²ΡΡΠ²Π»Π΅Π½ΠΈΡ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈ ΡΠΊΡΡΡΠΎ ΠΏΡΠΎΡΠ΅ΠΊΠ°ΡΡΠΈΡ ΠΌΠΈΠ½ΠΈΠΌΠ°Π»ΡΠ½ΡΡ ΡΠΎΡΠΌ Π ΠΠ ΠΈ CIS… Π§ΠΈΡΠ°ΡΡ Π΅ΡΡ >
Π‘ΠΏΠΈΡΠΎΠΊ Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΡ
- ΠΡΡΠ°ΠΌΠΎΠ½ΠΎΠ²Π° Π.Π. Π ΠΎΠ»Ρ ΠΈΠΌΠΌΡΠ½ΠΎΡΠ΅Π½ΠΎΡΠΈΠΏΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΠΎΠΏΡΡ ΠΎΠ»Π΅Π²ΡΡ ΠΊΠ»Π΅ΡΠΎΠΊ Π² Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠ΅ ΠΈ ΠΏΡΠΎΠ³Π½ΠΎΠ·Π΅ ΡΠ°ΠΊΠ° ΠΌΠΎΠ»ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ: ΠΠ²ΡΠΎΡΠ΅Ρ. Π΄ΠΈΡΡ. Π΄-ΡΠ° ΠΌΠ΅Π΄. Π½Π°ΡΠΊ. Π., 2003.
- ΠΡΡΠ°ΠΌΠΎΠ½ΠΎΠ²Π° Π.Π., Π’ΡΠΏΠΈΡΠΈΠ½ H.H., ΠΠ°Π΄Π°Π³ΠΈΠ΄Π·Π΅ Π. Π. ΠΈ Π΄Ρ. Π ΠΎΠ»Ρ ΡΠΏΠΈΡΠ΅Π»ΠΈΠ°Π»ΡΠ½ΡΡ Π°Π½ΡΠΈΠ³Π΅Π½ΠΎΠ² Π² Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠ΅ ΠΈ ΡΡΠ°Π΄ΠΈΡΠΎΠ²Π°Π½ΠΈΠΈ ΡΠ°ΠΊΠ° ΠΌΠΎΠ»ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ // ΠΡΡ ΠΈΠ² ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΠΈ. 2002. — № 6.
- ΠΠΎΠΆΠΎΠΊ A.A., Π‘Π΅ΠΌΠΈΠ³Π»Π°Π·ΠΎΠ² Π. Π€., Π‘Π΅ΠΌΠΈΠ³Π»Π°Π·ΠΎΠ² Π. Π. ΠΈ Π΄Ρ. Π€Π°ΠΊΡΠΎΡΡ ΠΏΡΠΎΠ³Π½ΠΎΠ·Π° ΠΏΡΠΈ ΡΠ°ΠΊΠ΅ ΠΌΠΎΠ»ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ // Π‘ΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½Π°Ρ ΠΎΠ½ΠΊΠΎΠ»ΠΎΠ³ΠΈΡΡ 2005. — № 1 (7). — Π‘.4−9.
- ΠΠΎΠ»ΡΠ΅Π½ΠΊΠΎ H.H., Π‘Π°Π²ΠΎΡΡΠΈΠΊΠΎΠ²Π° Π. Π. ΠΠΌΠΌΡΠ½ΠΎΡΠΈΡΠΎΡ ΠΈΠΌΠΈΡΠ΅ΡΠΊΠΎΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ ΠΏΡΠΈ ΡΠ°ΠΊΠ΅ ΠΌΠΎΠ»ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ // ΠΠ°ΠΌΠΌΠΎΠ»ΠΎΠ³ΠΈΡ. 2006. — № 4.
- ΠΠ΅ΡΡΡΠ΅ΠΉΠ½ Π.Π‘., ΠΡΡΠ»ΠΈΠ½ΡΠΊΠΈΠΉ Π. Π. Π’ΠΊΠ°Π½Π΅Π²ΡΠ΅ ΠΌΠ°ΡΠΊΠ΅ΡΡ ΠΊΠ°ΠΊ ΡΠ°ΠΊΡΠΎΡΡ ΠΏΡΠΎΠ³Π½ΠΎΠ·Π° ΠΏΡΠΈ ΡΠ°ΠΊΠ΅ ΠΌΠΎΠ»ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ // ΠΡΠ°ΠΊΡ. ΠΎΠ½ΠΊΠΎΠ»ΠΎΠ³ΠΈΡ. 2002. — Π’. Π, № 1.-Π‘.38−44.
- ΠΡΠΌΠΈΠ»ΠΎΠ²Π° Π. Π. Π ΠΎΠ»Ρ ΡΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΠΎΠΉ ΠΏΠ°ΡΠΎΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΠΈ Π² Ρ Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΡΡΠΈΠΊΠ΅ ΡΠ°ΠΊΠ° ΠΌΠΎΠ»ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ // ΠΡΠ°ΠΊΡ. ΠΎΠ½ΠΊΠΎΠ»ΠΎΠ³ΠΈΡ. 2002.- Π’. Π, № 1.-Π‘. 15−20.
- ΠΡΡΠ»ΠΈΠ½ΡΠΊΠΈΠΉ Π.Π., ΠΠ΅ΡΡΡΠ΅ΠΉΠ½ Π. Π‘. Π‘ΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΡΠ΅ Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎΡΡΠΈ ΠΌΠΎΠ»Π΅ΠΊΡΠ»ΡΡΠ½ΠΎ-Π±ΠΈΠΎΡ ΠΈΠΌΠΈΡΠ΅ΡΠΊΠΈΡ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠ² ΠΎΡΠ΅Π½ΠΊΠΈ Π±ΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ «ΠΏΠΎΠ²Π΅Π΄Π΅Π½ΠΈΡ» ΡΠ°ΠΊΠ° ΠΌΠΎΠ»ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ // ΠΠ΅ΡΡΠ½. Π ΠΠΠ.- 2001.- № 9.- Π‘.65−70.
- Π‘Π΅ΠΌΠΈΠ³Π»Π°Π·ΠΎΠ² Π.Π€., ΠΠ΅ΡΠ½ΠΈΠ½ Π. Π., ΠΠΎΠΈΡΠ΅Π΅Π½ΠΊΠΎ Π. Π. ΠΠΈΠ½ΠΈΠΌΠ°Π»ΡΠ½ΡΠΉ ΡΠ°ΠΊ ΠΌΠΎΠ»ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ. Π‘ΠΠ±: ΠΠΈΠΏΠΏΠΎΠΊΡΠ°Ρ, 1992. — 240 Ρ.
- Π‘Π΅ΠΌΠΈΠ³Π»Π°Π·ΠΎΠ² Π.Π€. ΠΠ½Π°ΡΠ΅Π½ΠΈΠ΅ ΠΏΡΠΎΠ³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΈΡ ΠΈ ΠΏΡΠ΅Π΄ΡΠΊΠ°Π·ΡΠ²Π°ΡΡΠΈΡ ΡΠ°ΠΊΡΠΎΡΠΎΠ² ΠΏΡΠΈ Π²ΡΠ±ΠΎΡΠ΅ Π»Π΅ΡΠ΅Π½ΠΈΡ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ ΠΌΠ΅ΡΠ°ΡΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΠΌ ΡΠ°ΠΊΠΎΠΌ ΠΌΠΎΠ»ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ // ΠΡΠ°ΠΊΡ. ΠΎΠ½ΠΊΠΎΠ»ΠΎΠ³ΠΈΡ.- 2000.- № 2. Π‘.26−30.
- Π‘Π΅ΠΌΠΈΠ³Π»Π°Π·ΠΎΠ² Π.Π. ΠΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠ°Ρ Ρ Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΡΡΠΈΠΊΠ° ΠΈ Π»Π΅ΡΠ΅Π½ΠΈΠ΅ Π½Π΅ΠΈΠ½Π²Π°Π·ΠΈΠ²Π½ΡΡ ΠΈ ΠΌΠΈΠ½ΠΈΠΌΠ°Π»ΡΠ½ΡΡ ΠΈΠ½Π²Π°Π·ΠΈΠ²Π½ΡΡ ΡΠΎΡΠΌ ΡΠ°ΠΊΠ° ΠΌΠΎΠ»ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ. -Π‘ΠΠ±.: ΠΡΠΊΡΠ»Π°ΠΏ, 2004.
- Π‘ΡΠ΅ΠΏΠ°Π½ΠΎΠ²Π° Π.Π., ΠΠ°Π³ΡΠ΅ΠΊΠΎΠ²Π° Π. Π., ΠΡΠΌΠΈΠ»ΠΎΠ²Π° Π. Π. ΠΈ Π΄Ρ. ΠΠΎΠ»Π΅ΠΊΡΠ»ΡΡΠ½ΠΎ-Π±ΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΌΠ°ΡΠΊΠ΅ΡΡ ΠΊΠ°ΠΊ ΡΠ°ΠΊΡΠΎΡΡ ΠΏΡΠΎΠ³Π½ΠΎΠ·Π° ΠΏΡΠΈ ΡΠ°ΠΊΠ΅ ΠΌΠΎΠ»ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ I-IIA ΡΡΠ°Π΄ΠΈΠΈ // ΠΡΡ . ΠΏΠ°ΡΠΎΠ»ΠΎΠ³. 2003. — № 3. — Π‘. 14−18.
- Π’ΡΠΏΠΈΡΡΠ½ H.H., ΠΠ°ΡΠΈΠ»ΡΠ΅Π² Π. Π., ΠΠ³Π½Π΅ΡΡΠ±ΠΎΠ² H.A. ΠΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ΅ Π·Π½Π°ΡΠ΅Π½ΠΈΠ΅ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ ΡΡΠ°Π½ΡΡΠ΅ΡΡΠΈΠ½ΠΎΠ²ΠΎΠ³ΠΎ ΡΠ΅ΡΠ΅ΠΏΡΠΎΡΠ° Π½Π° ΠΊΠ»Π΅ΡΠΊΠ°Ρ ΡΠ°ΠΊΠ° ΠΌΠΎΠ»ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ // ΠΠΎΠ²ΠΎΠ΅ Π² ΠΎΠ½ΠΊΠΎΠ»ΠΎΠ³ΠΈΠΈ /ΠΠΎΠ΄ ΡΠ΅Π΄. Π. Π. ΠΠΎΠ΄Π΄ΡΠ±Π½ΠΎΠΉ, H.A. ΠΠ³Π½Π΅ΡΡΠ±ΠΎΠ²Π°. ΠΠΎΡΠΎΠ½Π΅ΠΆ, 2001. ΠΡΠΏ. 5. — Π‘. 197−209.
- Π§Π΅ΠΏΡΡΠ΅Π²Π° Π’.Π., ΠΠ΅Π»ΡΠΏΡΠ΅ΠΉΠ½ Π. Π., ΠΡΠΌΠΈΠ»ΠΎΠ²Π° Π―. Π. ΠΈ Π΄Ρ. ΠΠΊΡΠΏΡΠ΅ΡΡΠΈΡ ΠΌΠΎΠ»Π΅ΠΊΡΠ» ΠΌΠ΅ΠΆΠΊΠ»Π΅ΡΠΎΡΠ½ΠΎΠΉ Π°Π΄Π³Π΅Π·ΠΈΠΈ Π-ΠΊΠ°Π΄Ρ Π΅ΡΠΈΠ½Π° ΠΈ Π -ΠΊΠ°ΡΠ΅Π½ΠΈΠ½Π° Π² ΠΈΠ½ΡΠΈΠ»ΡΡΡΠ°ΡΠ΅ ΠΊΠ°ΡΡΠΈΠ½ΠΎΠΌΡ ΠΌΠΎΠ»ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ // ΠΡΡ ΠΈΠ² ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΠΈ. 2003. — № 3.
- ΠΠ»Π»ΠΈΠ½ΠΈΠ΄ΠΈ Π.Π., ΠΠ½ΠΈΠΊΠ΅Π΅Π²Π° Π. Π., ΠΠΎΠ½ΡΠ°ΡΠΎΠ²Π° O.A. ΠΈ Π΄Ρ. ΠΠΌΠΌΡΠ½ΠΎΠ³ΠΈΡΡΠΎΡ ΠΈΠΌΠΈΡΠ΅ΡΠΊΠΎΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ ΡΠ΅ΡΠ΅ΠΏΡΠΎΡΠΎΠ² ΡΡΡΡΠΎΠ³Π΅Π½ΠΎΠ² ΠΈΠΏΡΠΎΠ³Π΅ΡΡΠ΅ΡΠΎΠ½Π° Π² ΡΠ°ΠΊΠ΅ ΠΌΠΎΠ»ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ // ΠΠΎΠΏΡ. ΠΎΠ½ΠΊΠΎΠ»ΠΎΠ³ΠΈΠΈ. 2004. — Π’. 50, № 2. — Π‘.234−236.
- Abbey Π‘.Π., Borowsky A.D., Gregg J.P. et al. Preclinical imaging of mammary intraepithelial neoplasia with positron emission tomography // J. Mammary Gland Biol. Neoplasia. -2006. -Vol.11 (2).-P.l37−149.
- Ackerman L.V., Katzenstein A.L. The concept of minimal breast cancer and the pathologist’s role in the diagnosis of «early carcinoma» // Cancer.-1977. Vol.39. — P.2755−2763.
- Akashi-Tanaka S., Shien Π’., Tsukagoshi S. et al. Whole-breast volume perfusion images using 256-row multislice computed tomography: visualization of lesions with ductal spread // Breast Cancer. 2009. — Vol.16 (1). — P.62−67.
- Akli S., Zheng P.J., Multani A.S. et al. Tumor-specific low molecular weight forms of cyclin E induce genomic instability and resistance to p21, p27, and antiestrogens in breast cancer // Cancer Res. 2004. — Vol.64. — P.3198−3208.
- Albonico G., Querzoli P., Ferretti S. et. al. Biological profile of in situ breast cancer investigated by immunohistochemical technique // Cancer Detect. Prev. -1998.-Vol.22.-P.313−318.
- Alkarain A., Jordan R., Slingerland J. p27 deregulation in breast cancer: prognostic significance and implications for therapy // J. Mammary Gland Biol. Neoplasia. 2004. — Vol.9. — P.67−80.
- Allred D.C., Mohsin S.K., Fuqua S.A. Histological and biological evolution of human premalignant breast disease // Endocr. Relat. Cancer. 2001. -Vol.8 (1).-P.47−61.
- Allred D.C. et al. Accumulation of mutant p53 is associated with increased proliferation and poor clinical outcome in node negative breast cancer // J. Natl. Cancer Inst. 1993. — Vol.85.- P.200−206.
- Andersen J.A. Lobular carcinoma in situ: an approach to rational treatment // Cancer. 1977. — Vol. 39. — P.2597−2602.
- Andersen J.A. Lobular carcinoma in situ of the breast with ductal involvement. Frequency and possible influence on prognosis // Acta Pathol. Microbiol. Scand. 1974.-Vol.82. -P.655−662.
- Andersen J.A. Lobular carcinoma in situ. A long-term follow-up in 52 cases // Acta Pathol. Microbiol. Scand. 1974. — Vol.82. — P.519−533.
- Andersen J.A., Schiodt T. On the concept of carcinoma in situ of the breast // Pathol. Res. Pract. 1980. — Vol. 166. — P. 407−414.
- Andersen J.A., Vendelboe M.L. Cytoplasmic mucous globules in lobular carcinoma in situ. Diagnosis and prognosis // Am. J. Surg. Pathol. 1981. — Vol.5 (3).-P.251−255.
- Anon. Consensus Conference on the classification of ductal carcinoma in situ. The Consensus Conference Committee // Cancer. 1997. — Vol.80 (9). -P.1798−1802.
- Antuofermo E., Miller M.A., Pirino S. et al. Spontaneous mammary intraepithelial lesions in dogs a model of breast cancer // Cancer Epidemiol. Biomarkers Prev. — 2007. — Vol.16 (11). — P.2247−2256.
- Arriola E., Rodriguez-Pinilla S.M., Lambros M.B. et al. Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer // Breast Cancer Res Treat. -2007. Vol.106 (2). — P.181−189.
- Ashikari R., Hajdu S.I., Robbins G.F. Intraductal carcinoma of the breast (1960−1969)//Cancer (Philad.).- 1971.-Vol. 28.-P. 1182−1187.
- Ashikari R. et al. A clinicopathologic study of atypical lesion of the breast further follow-up // Pathol. Res. Pract. 1980. — Vol.166, № 4. — P. 481 490.
- Assersohn L., Salter J., Powles T.J. et al. Studies of the potential utility of Ki67 as a predictive molecular marker of clinical response in primary breast cancer // Breast Cancer Res. Treat. 2003. -Vol.82. — P. 113−123.
- Attene F., Scognamillo F., Trignano E. et al. In situ carcinomas of the breast: clinical features and therapeutic strategies // Ann. Ital. Chir. 2006. -Vol.77 (1).-P.3−10.
- Aubele M.M., Cummings M.C., Mattis A.E. et al. Accumulation of chromosomal imbalances from intraductal proliferative lesions to adjacent in situ and invasive ductal breast cancer // Diagn. Mol. Pathol. 2000. — Vol.9 (1). -P.14−19.
- Bagwell C.B., Clark G.M., Spyratos F. et al. Optimizing flow cytometric DNA ploidy and S-phase fraction as independent prognostic markers for node-negative breast cancer specimens // Cytometry. 2001. — Vol.46. -P.121−135.
- Baldetorp B., Bendahl P.O., Ferno M., Stal O. Improved DNA flow cytometric, DNA ploidy, and S-phase reproducibility between 15 laboratories in analysis of breast cancer using generalized guidelines // Cytometry. 2003. -Vol.56A. — P. 1−7.
- Bane A.L., Pinnaduwage D., Colby S. et al. Expression profiling of familial breast cancers demonstrates higher expression of FGFR2 in BRCA2-associated tumors // Breast Cancer Res Treat. 2009. — Vol.117 (1).- P.183−191.
- Bankfalvi A. HER-2 diagnostics // Mag. Onkol. 2002.- Vol.46, № 1 P. ll-15.
- Bankhead A., Magnuson N.S., Heckendorn R.B. Cellular automaton simulation examining progenitor hierarchy structure effects on mammary ductal carcinoma in situ // J. Theor. Biol. 2007. — Vol.246(3). — P.491−498.
- Barbareschi M., Van Tinteren H., Mauri F.A. et al. p27(kipl) expression in breast carcinomas: an immunohistochemical study on 512 patients with long-term follow-up // Int. J. Cancer. 2000. — Vol.89. — P.236−241.
- Barnes A., Pinder S.E., Bell J.A. et al. Expression of p27kipl in breast cancer and its prognostic significance // J. Pathol.- 2003. Vol.201. — P.451−459.
- Barnes NL, Boland GP, Davenport A, Knox WF, Bundred NJ: Relationship between hormone receptor status and tumour size, grade and comedo necrosis in ductal carcinoma in situ. Br J Surg 2005, 92:429−434
- Beckmann M.W., Niederacher D., Schnurch H.G. et al. Multistep carcinogenesis of breast cancer and tumor heterogeneity // J. Mol. Med. 1997. -Vol.75 (6). — P.429−439.
- Ben Hassouna J., Damak T., Ben Slama A. et al. Breast carcinoma arising within fibroadenomas. Report of four observations // Tunis Med. 2007. -Vol.85 (10). — P.891−895.
- Bentz J.S., Yassa N., Clayton F. Pleomorphic lobular carcinoma of the breast: clinicopathologic features of 12 cases // Mod. Pathol. 1998. — Vol. 11.-P. 814−822.
- Berman H., Zhang J., Crawford Y.G. et al. Genetic and epigenetic changes in mammary epithelial cells identify a subpopulation of cells involved in early carcinogenesis // Cold Spring Harb Symp Quant Biol. 2005. — Vol.70. -P.317−327.
- Berx G., Becker K.F., Hofler H., Van Roy F. Mutations of the human E-cadherin (CDH1) gene // Hum. Mutat. 1998. — Vol.12. — P.226−237.
- Berx G., Cleton-Jansen A.M., Nollet F. et. al. E-cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancer // EMBO J. 1995.-Vol.14.-P.6107−6115.
- Berx G., Cleton-Jansen A.M., Strumane K. et. al. E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain // Oncogene. 1996. — Vol.13. -P.1919−1925.
- Bianchi S., Vezzosi V. Microinvasive carcinoma of the breast // Pathol. Oncol. Res. 2008. — Vol.14 (2). — P. 105−111.
- Bluff J.E., Menakuru S.R., Cross S.S. et al. Angiogenesis is associated with the onset of hyperplasia in human ductal breast disease // Br. J. Cancer. -2009. -Vol. 101 (4). P.666−672.
- Bocker W., Hungermann D., Weigel S. et al. Immunohistochemistry in breast pathology: differential diagnosis of epithelial breast lesions // Pathologe. 2009.-Vol.30 (1).-P.13−19.
- Bocker W., Hungermann D., Weigel S. et al. Atypical ductal hyperplasia and atypical epithelial proliferation of ductal type // Pathologe. -2009.-Vol.30 (l).-P.42−48.
- Bodian C.A., Perzin K.H., Lattes R. Lobular neoplasia. Long term risk of breast cancer and relation to other factors // Cancer. 1996. — Vol.78 (5). -P.1024−1034.
- Bodian C.A., Perzin K.H., Lattes R. et al. Prognostic significance of benign proliferative breast disease // Cancer. 1993. — Vol.71 (12). — P.3896−3907.
- Boecker W., Buerger H., Schmitz K. et al. Ductal epithelial proliferations of the breast: a biological continuum? Comparative genomic hybridization and high-molecular-weight cytokeratin expression patterns // J. Pathol. -2001. -Vol.195 (4).-P.415−421.
- Bottini A., Berruti A., Bersiga A. et al. p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients // Clin. Cancer Res. 2000. — Vol.6. -P.2751−2758.
- Bratthauer G.L., Moinfar F., Stamatakos M.D. et. al. Combined E-cadherin and high molecular weight citokeratin immunoprofile differentiates lobular, ductal and hybrid mammary intraepithelial neoplasia // Hum. Pathol. -2002. Vol.33. — P. 620−627.
- Bratthauer G.L., Tavassoli F.A. Lobular intraepithelial neoplasia: previously unexplored aspects assessed in 775 cases and their clinical implications // Virchows Arch. 2002. — Vol. 440 (2). — P.134−138.
- Broet P., Romain S., Daver A. et al. Thymidine kinase as a proliferative marker: clinical relevance in 1,692 primary breast cancer patients // J. Clin. Oncol. 2001. — Vol.19. — P.2778−2787.
- Brown D.C., Gatter K.C. Ki67 protein: the immaculate deception? // Histopathology. 2002. — Vol. 40. — P.2−11.
- Brown P.W., Silverman J., Owens E. et al. Intraductal «noninfiltrating» carcinoma of the breast // Arch. Surg. 1976. — Vol. 111. — P. 1063−1067.
- Buchholtz T.A., Davis D.W., McConcey DJ. et al. Chemotherapy-induced apoptosis and Bcl-2 levels correlate with breast cancer response to chemotherapy // Cancer. 2003 — Vol.9. — P. 33−41.
- Buerger H., Mommers E.C., Littmann R. et al. Ductal invasive G2 and G3 carcinomas of the breast are the end stages of at least two different lines of genetic evolution // J. Pathol. 2001. — Vol.94 (2). — P. 165−170.
- Buzdar A.U., Valero V., Theriault R.L. et al. Pathological complete response to chemotherapy is related to hormone receptor status // Proc. Breast Cancer Conf. San Antonio, 2003.
- Calzada L., Martinez J.M., Sandoval T. Hormone-related factors associated with hormone receptor levels in breast cancer // Gynecol. Obstet. Invest. 2001, — Vol.52, № 4.- P.264−268.
- Campiglio M., Somenzi G., Olgiati C. et al. Role of proliferation in HER2 status predicted response to doxorubicin // Int. J. Cancer. 2003. — Vol. 105. -P.568−573.
- Carpenter R., Gibbs N., Matthews J. et al. Importance of cellular DNA content in pre-malignant breast disease and pre-invasive carcinoma of the female breast //Br. J. Surg. 1987. — Vol.74 (10). -P.905−906.
- Carter C.L., Corle D.K., Micozzi M.S. et al. A prospective study of the development of breast cancer in 16,692 women with benign breast disease // Am. J. Epidemiol. 1988. — Vol.128 (3). — P.467−477.
- Casimiro M., Rodriguez O., Pootrakul L. et al. Albanese C. ErbB-2 induces the cyclin D1 gene in prostate epithelial cells in vitro and in vivo // Cancer Res. 2007. — Vol.67 (9). — P.4364−4372.
- Ceccarelli C., Santini D., Chieco P. et al. Quantitative p21(waf-l)/p53 immunohistochemical analysis defines groups of primary invasive breast carcinomas with different prognostic indicators // Int. J. Cancer. 2001. — Vol. 95. -P.128−134.
- Chang J., Ormerod M., Powles T.J. et al. Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma // Cancer. 2000. — Vol.89 (11). — P.2145- 2152.
- Chappius P.C., Cyclin E expression in breast cancer: predicting germline BRCA1 mutations, prognosis and response to treatment // Ann. Oncol. -2005.- Vol.16, № 5.- P.735−742.
- Cheatle G.L., Cutler M. Tumors of the breast. Philadelphia: J.B. Lippincott, 1931.
- Chen Y.Y., Hwang E.S., Roy R. et al. Genetic and phenotypic characteristics of pleomorphic lobular carcinoma in situ of the breast // Am. J. Surg. Pathol. -2009. Vol.33 (11). -P.1683−1694.
- Citoler P., Zippel H.H. Carcinoma in situ of the breast // Verh. Dtsch. Ges. Pathol. 1975. — Vol.59. — P.549.
- Cobanoglu U. et al. Correlation of E-cadherin expression with clinicopathological parameters in breast carcinoma // Saudi Med J.- 2004, — Vol.25, № 8.-P. 1024−1027.
- Come C., Magnino F., Bibeau F. et al. Snail and slug play distinct roles during breast carcinoma progression // Clin. Cancer Res. 2006. -Vol.12(18). — P.5395−5402.
- Contreras A., Sattar H. Lobular neoplasia of the breast: an update // Arch. Pathol. Lab. Med. -2009.-Vol.133 (7).-P.l 116−1120.
- Crawford L.V., Pim D.C., Bulbrook R.D. Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer // Int. J. Cancer.- 1982.- Vol.30, № 4. P.403−408.
- Crissman J.D., Visscher D.W., Kubus J. Image cytophotometric DNA analysis of atypical hyperplasias and intraductal carcinomas of the breast // Arch. Pathol. Lab Med. -1990. -Vol.114 (12).-P.1249−1253.
- Cummings M.C., Aubele M., Mattis A. et al. Increasing chromosome 1 copy number parallels histological progression in breast carcinogenesis // Br. J. Cancer. 2000. — Vol.82 (6). — P. 1204−1210.
- Dabbs D.J. Diagnostic immunohistochemistry. Churchill Livingstone, 2002.- 676 p.
- Da Silva L., Parry S., Reid L. et al. Aberrant expression of E-cadherin in lobular carcinomas of the breast // Am. J. Surg. Pathol. 2008. — Vol. 32 (5). -P.773−783.
- De Mascarel I., MacGrogan G., Vincent-Salomon A. et al. Epithelial atypia: a marker risk of concomitant or subsequent breast carcinoma? // J. Clin. Oncol. -2008.-Vol.26 (27). P.4514−4515.
- De Roos M.A., De Bock G.H., De Vries J. et al. p53 overexpression is a predictor of local recurrence after treatment for both in situ and invasive ductal carcinoma of the breast // J. Surg. Res. 2007. — Vol.140 (1). — P. 109−114.
- Ding Y., Ruan Q. The value of p63 and CK5/6 expression in the differential diagnosis of ductal lesions of breast // J. Huazhong Univ. Sei Technolog. Med. Sei. 2006. — Vol.26 (4). — P.405−407.
- Dupont W.D., Page D.L. Breast cancer risk associated with proliferative disease, age at first birth, and a family history of breast cancer // Am. J. Epidemiol. 1987. — Vol.125 (5). — P.769−779.
- Dupont W.D., Page D.L. Risk factors for breast cancer in women with proliferative breast disease//N. Engl. J. Med. 1985. — Vol.312 (3). -P. 146−151.
- Durbecq V., Desmed C., Paesmans M. et al. Correlation between topoisomerase-II alpha gene amplification and protein expression in HER-2 amplified breast cancer // Int. J. Oncol. 2004. — Vol.25. — P. 1473−1479.
- Elledge R.M. et al. bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group study // J. Clin. Oncol. 1997. — Vol.15. — P.1916−1922.
- Ellis I.O., Tavassoli F.A. Microinvasive carcinoma// WHO classification of tumours. Patology and Genetics of tumours of the breast and female genital organs. IARC-Press. Lyon, 2003, -P.74−75.
- Elwood V.E., Craig V.J. The Estrogen Receptor: A Model for Molecular Medicine // Clinical Cancer Research. 2003.- Vol. 9.- P. 1980−1989.
- Eriksson E.T., Schimmelpenning H., Aspenblad U. et al. Immunohistochemical expression of the mutant p53 protein and nuclear DNA content during the transition from benign to malignant breast disease // Hum. Pathol. -1994.-Vol.25 (11).-P.1228−1233.
- Ernster V.L., Barclay J., Kerlikowske K. et al. Mortality among women with ductal carcinoma in situ of the breast in the population-based surveillance, epidemiology and end results program // Arch. Intern Med. 2000. -Vol.160 (7). -P.953−958.
- Esslimani-Sahla M. Increased estrogen receptor betacx expression during mammary carcinogenesis // Clin. Cancer. Res.- 2005.- Vol.11, № 9.-P.3170−3174.
- Esteva F.G., Hortobagyi G.N. Prognostic markers in early breast cancer // Breast Cancer Res.- 2004.- Vol.6, № 3.- P. 109−118.
- Eusebi V., Azzopardi J.G. Lobular endocrine neoplasia in fibroadenoma of the breast // Histopathology. 1980. — Vol. 4. — P. 413−428.
- Evans A.J., Pinder S.E., Ellis I.O. et al. Screen detected ductal carcinoma in situ (DCIS): overdiagnosis or an obligate precursor of invasive disease? // J. Med. Screen. 2001. — Vol.8 (3). — P.149−151.
- Fackler M.J., Rivers A., Teo W.W. et al Hypermethylated genes as biomarkers of cancer in women with pathologic nipple discharge // Clin. Cancer Res. 2009. — Vol.15 (11). — P.3802−3811.
- Farnie G., Clarke R.B. Mammary stem cells and breast cancer role of Notch signalling// Stem Cell Rev. -2007. — Vol.3(2).-P.169−175.
- Felty Q., Singh K.P., Roy D. Estrogen-induced G (l)/S transition of G (0)-arrested estrogen-dependent breast cancer cells is regulated by mitochondrial oxidant signalling // Oncogene. 2005.- May 16.
- Fisher E.R., Constantino J., Fisher B. et. al. Pathologic findings from the National Surgical Ajuvant Breast Project (NSABP) Protocol B-17. Five-year observation concerning lobular carcinoma in situ // Cancer. 1996. — Vol. 78. — P. 1403−1416.
- Fitzgibbons P.L., Page D.L., Weaver D. et al. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. // Arch. Pathol. Lab. Med. 2000. — Vol.124 (7). — P.966−978.
- Fitzgibbons M.D. Prognostic Factors in Breast Cancer // Arch. Pathol. Lab. Med. 2000. — Vol.124. — P.966−978.
- Foote F.W., Stewart F.W. Lobular carcinoma in situ //Am. J. Pathol. -1941.- Vol.17. -P.491 -495.
- Galager H.S. The developmental Pathology of Breast Cancer // Cancer (Philad.) 1980. — Vol.46, № 4. — P. 905−907.
- Geffroy N. et al. Cell cycle regulation of breast cancer cells through estrogen-induced activities of ERK and Akt protein kinases // Mol. Cell Endocrinol. 2005.- Vol.237, № 1.- P. l 1−23.
- Giri D.D., Dundas S.A., Nottingham J.F., Underwood J.C. Oestrogen receptors in benign epithelial lesions and intraduct carcinomas of the breast: an immunohistological study // Histopathology. 1989. — Vol. 15. — P.575−584.
- Goldhirsch A., Wood W.C., Gelber R.D. et al. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer//J. Clin. Oncol. 2003. — Vol. 21. -P.3357−3365.
- Gong G., DeVries S., Chew K.L. et al. Genetic changes in paired atypical and usual ductal hyperplasia of the breast by comparative genomic hybridization // Clin. Cancer Res. 2001. — Vol.7 (8). — P.2410−2444.
- Goradini D., Diadone M.G. Biomolecular prognostic factors in breast cancer//Curr. Opin. Obstet. Gynecol. 2004.- Vol.16., № 1.-P.49−55.
- Green A.R., Krivinskas S., Young P. et al. Loss of expression of chromosome 16q genes DPEP1 and CTCF in lobular carcinoma in situ of the breast // Breast Cancer Res Treat. 2009. — Vol.113 (1). — P.59−66.
- Grundmann E. Precancer-histology trends and prospects // Z Krebsforsch Klin. Onkol. Cancer Res. Clin. Oncol. — 1976. — Vol.85 (1). -P.l-11.
- Guemes A., Sousa R., Cachon R. et al. Minimally invasive breast surgery. Breast reconstruction using pure muscular latissimus dorsi flap // Cir Esp. 2008. — Vol.83 (2). — P.85−88.
- Gump F.E. Lobular carcinoma in situ. Pathology and treatment // Surg. Clin. North. Am. 1990. — Vol. 70. — P. 873−883.
- Gupta SK, Douglas-Jones AG, Jasani B, Morgan JM, Pignatelli M, Mansel RE: E-cadherin (E-cad) expression in duct carcinoma in situ (DCIS) of the breast. Virchows Arch 1997, 430:23−28
- Guth A.A., Mercado C., Roses D.F. et al. Microinvasive breast cancer and the role of sentinel node biopsy: an institutional experience and review of the literature // Breast J. 2008. — Vol.14 (4). — P.335−339.
- Haagensen C.D. Diseases of the Breast. 3nd. ed., W.B. Philadelphia: Saunders, 1986.
- Haagensen C.D., Lane N., Lattes R. Neoplastic proliferation of the epithelium of the mammary lobules: adenosis, lobular neoplasia and small cell carcinoma // Surg. Clin. North. Am. 1972. — Vol. 52. — P.497−524.
- Haagensen C.D., Lane N., Lattes R., Bodian C. Lobular neoplasia (socalled lobular carcinoma in situ) of the breast // Cancer. 1978. — Vol.42 (2). -P.737−769.
- Habel L.A., Moe R.E., Daling J.R. et al. Risk of contralateral breast cancer among women with carcinoma in situ of the breast // Ann. Surg. 1997. -Vol.225.-P.69−75.
- Hanley K., Wang J., Bourne P. et al. Lack of expression of androgen receptor may play a critical role in transformation from in situ to invasive basal subtype of high-grade ductal carcinoma of the breast // Hum Pathol. 2008. -Vol.39 (3).-P.386−392.
- Hannemann J., Kristel P., Van Tinteren H. et al. Molecular subtypes of breast cancer and amplification of topoisomerase II alpha: predictive role in dose intensive adjuvant chemotherapy // Br. J. Cancer. 2006. — Vol.95 (10). -P.1334−1341.
- Hannemann J, Velds A, Halfwerk JB et al. Classification of ductal carcinoma in situ by gene expression profiling. Breast Cancer Res 2006- 13: 23 292 334
- Hansen R.K., Bissell M.J. Tissue archistructure and breast cancer: the role of extracellular matrix and steroid hormones // Endocrine-Related Cancer. -2000.-Vol.7. P.95−113.
- Hawkins D.S., Demers G.W., Galloway D.A. Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents // Cancer Res. 1996. -Vol.56. — P.892−898.
- Hayes D.F., Thor A.D. C-erbB-2 in breast cancer: development of a clinically useful marker // Semin. Oncol. 2002.- № 3.- P.231−245.
- Heffelfinger S.C., Yassin R., Miller M.A. et al. Cyclin Dl, retinoblastoma, p53, and Her2/neu protein expression in preinvasive breastpathologies: correlation with vascularity // Pathobiology. 2000. — Vol. 68 (3). -P.129−136.
- Hellemans P. et al. Prognostic value of bcl-2 expression in invasive breast cancer // Br. J. Cancer.- 1995.- Vol.72.- P.354−360.
- Hetelekidis S., Schnitt S.J., Morrow M., Harris J.R. Management or ductal carcinoma in situ // Cancer J. Clinic. 1995. — Vol. 45. — P. 244−253.
- Hilson J.B., Schnitt S.J., Collins L.C. Phenotypic alterations in ductal carcinoma in situ-associated myoepithelial cells: biologic and diagnostic implications // Am. J. Surg. Pathol. 2009. — Vol.33 (2). — P.227−232.
- Hoang J.K., Hill P., Cawson J.N. Can mammographic findings help discriminate between atypical ductal hyperplasia and ductal carcinoma in situ after needle core biopsy? // Breast. 2008. — Vol 17 (3). — P.282−288.
- Holland R., Faverly D.R. Whole-organ studies // In. Silverstein M.J., ed. Ductal carcinoma in situ of the breast. Baltimore: Williams & Wilkins, 1997. -P. 233−240.
- Howard E.M. Correlation and expression of p53, HER-2, vascular endothelial growth factor (VEGF), and E-cadherin in a high-risk breast-cancer population // Int. J. Clin. Oncol.- 2004.- Vol.9, № 3.- P. 154−160.
- Howard E.M. et al. Expression of e-cadherin in high-risk breast cancer //J. Cancer Res. Clin. Oncol. 2005. — Vol.131, № 1.-P.14−18.
- Huang H.J. Association between tumor characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer // Clin. Pathol.- 2005.- Vol.58, № 6.- P.611−616.
- Husemann Y., Geigl J.B., Schubert F. et al. Systemic spread is an early step in breast cancer // Cancer Cell. 2008. — Vol.13 (1). — P.58−68.
- Idvall I., Andersson C., Fallenius G. et al. Histopathological and cell biological factors of ductal carcinoma in situ before and after the introduction of mammographic screening // Acta Oncol. 2001. — Vol.40 (5). — P.653−659.
- Ikeda K., Inoue S. Estrogen receptors and their downstream targets in cancer // Arch. Histol. Cytol. 2004. — Vol.67, № 5. — P.435−442.
- Iqbal M., Davies M.P., Shoker B.S. et al. Subgroups of non-atypical hyperplasia of breast defined by proliferation of oestrogen receptor-positive cells //J.Pathol. -2001. Vol.193 (3).-P.333−338.
- Jaffer S., Orta L., Sunkara S. et al. Immunohistochemical detection of antiapoptotic protein X-linked inhibitor of apoptosis in mammary carcinoma // Hum Pathol. 2007. — Vol.38 (6). — P.8648−70.
- James T.A., Harlow S., Sheehey-Jones J. et al. Intraoperative ultrasound versus mammographic needle localization for ductal carcinoma in situ // Ann Surg Oncol. 2009. — Vol.16 (5). — P. 1164−1169.
- Jones C., Merrett S., Thomas V.A. et al. Comparative genomic hybridization analysis of bilateral hyperplasia of usual type of the breast //J. Pathol. 2003. — Vol. 199 (2). — P. 152−156.
- Jun-ichiro I., Eiichi M., Yalan L. et al. Prognostic Significance of CD55 Expression in Breast Cancer // Clin. Cancer Res. 2008. — Vol. 14. -P.4780−4786.
- Kanemaki Y., Kurihara Y., Okamoto K. et al. Ductal carcinoma in situ: correlations between high-resolution magnetic resonance imaging and histopathology // Radiat. Med. -2007.-Vol.25 (1).-P.l-7.
- Karayiannakis A J., Bastounis E.A., Chatzigianni E.B. et al. Immunohistochemical detection of oestrogen receptors in ductal carcinoma in situ of the breast // Eur. J. Surg. Oncol. 1996. — Vol.22 (6). — P.578−582.
- Kepple J, Henry-Tillman RS, Klimberg VS, Layeeque R, Siegel E, Westbrook K, Korourian S: The receptor expression pattern in ductal carcinoma in situ predicts recurrence. Am J Surg 2006,192:68−71.
- Kerlikowske K., Barclay J., Grady D. et al. Comparison of risk factors for ductal carcinoma in situ and invasive breast cancer // J. Natl. Cancer Inst. -1997.-Vol.89 (l).-P.76−82.
- Keshgegian A.A., Cnaan A. Proliferation markers in breast carcinoma: mitotic figure count, S-phase fraction, proliferating cell nuclear antigen, Ki-67 and MIB-1 //Am. J. Clin. Pathol. 1995. — Vol.104. — P.429.
- Keyomarsi K., Tucker S.L., Buchholz T.A. et al. Cyclin E and survival in patients with breast cancer // N. Engl. J. Med. 2002. — Vol.347. -P.1566−1575.
- Khalifeh I.M., Albarracin C., Diaz L.K. et al. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma // Am. J. Surg. Pathol. 2008. -Vol.32 (4).-P.544−552.
- Khan SA, Rogers MA, Khurana KK, Meguid MM, Numann PJ: Estrogen receptor expression in benign breast epithelium and breast cancer risk. J Natl Cancer Inst 1998, 90:37−42.
- Kim J.H., Ko E.S., Kim D.Y. et al. Noncalcified ductal carcinoma in situ: imaging and histologic findings in 36 tumors // J. Ultrasound Med. 2009. -Vol.28 (7). -P.903−910.
- Kraus F.T., Neubecker R.D. The differential diagnosis of papillary tumors of the breast // Cancer (Philad.). 1962. — Vol. 15. — P. 444−455.
- Krieger N., Hiatt R.A. Risk of breast cancer after benign breast diseases. Variation by histologic type, degree of atypia, age at biopsy, and length of follow-up // Am. J. Epidemiol. 1992. — Vol.135 (6). -P.619−631.
- Krogerus LA, Leivonen M, Haasto AL: Expression patterns of biologic markers in small breast cancers and preneoplastic breast lesions. Breast 2000, 9:281−285
- Kute T.E., Russell G.B., Zbieranski N. et al. Prognostic markers in nodenegative breast cancer: a prospective study // Cytometry. 2004. — Vol.59. -P.24−31.
- Lagios M.D., Margolin F.R., Westdahl P.R. et al. Mammographically detected duct carcinoma in situ. Frequency of local recurrence following tylectomy and prognostic effect of nuclear grade on local recurrence // Cancer. 1989. -Vol.63 (4). — P.618−624.
- Lagios M.D. Ductal carcinoma in situ: biological and therapeutic implications of classification // The Breast J. 1996. — Vol. 2, № 2. — P. 32−34.
- Lagios M.D. Ductal carcinoma in situ: Controversies in diagnosis, biology, and treatment // The Breast J. 1995. — Vol. 1, № 2. — P. 68−78.
- Lagios M.D. Heterogeneity of ductal carcinoma in situ: Relationship of grade and subtype analysis to local recurrence and risk of invasive transformation // Cancer Letters. 1995. — Vol. 90. — P. 97−102.
- Lakhani S.R. The transition from hyperplasia to invasive carcinoma of the breast // J. Pathol. 1999. — Vol.187 (3). — P.272−278.
- Lattes R. Lobular neopasia (lobular carcinoma in situ) of the breast. A histological entity of controversial clinical significance // Pathol. Res. Pract. -1980.-Vol.166,N4. -P. 415−429.
- Le Bouedec G., De Lapasse C., Mishellany F. et al. Ductal carcinoma in situ of the breast with microinvasion. Role of sentinel lymph node biopsy // Gynecol. Obstet. Fertil. 2007. — Vol.35 (4). — P.317−322.
- Lee A.H. The histological diagnosis of metastases to the breast from extramammary malignancies // J. Clin. Pathol. 2007. — Vol.60 (12). — P. 13 331 341.
- Lerma E., Peiro G., Ramon T. et al. Immunohystochemical heterogeneity of breast carcinomas negative for estrogen receptors, progesterone receptors and Her2/neu (basal-like breast carcinomas) // Mod. Pathol. 2007. -Vol.20 (11).-P.1200−1207.
- Lester T., Wang J., Bourne P. et al. Different panels of markers should be used to predict mammary Paget’s disease associated with in situ or invasive ductal carcinoma of the breast // Ann. Clin. Lab. Sci. 2009. — Vol.39 (1). -P. 17−24.
- Li H.C. Prognostic value of matrix metalloproteinases (MMP-2 and MMP-9) in patients with lymph node-negative breast carcinoma // Breast Cancer Res. Treat. 2004. — Vol.88, № 1. — P.75−85.
- Lindahl T., Landberg G., Ahlgren J. et al. Overexpression of cyclin E protein is associated with specific mutation types in the p53 gene and poor survival in human breast cancer // Carcinogenesis. 2004. — Vol.25. — P.375−380.
- Liu H., Jiang Y.X., Liu J.B. et al. Contrast-enhanced breast ultrasonography: imaging features with histopathologic correlation // J. Ultrasound Med. 2009. — Vol.28 (7). — P.911−920.
- Liu T., Niu Y., Yu Y. et al. Increased gamma-tubulin expression and P16INK4A promoter methylation occur together in preinvasive lesions and carcinomas of the breast // Ann. Oncol. 2009. — Vol.20 (3). — P.441−448.
- Liu Z.B., Wu J., Ping B. et al. Basal cytokeratin expression in relation to immunohistochemical and clinical characterization in breast cancer patients with triple negative phenotype// Tumori. -2009. Vol.95(l). -P.53−62.
- Livasy C.A., Perou C.M., Karaca G. et al. Identification of a basal-like subtype of breast ductal carcinoma in situ // Hum. Pathol. 2007. -Vol.38 (2). -P. 197−204.
- Londero V., Zuiani C., Furlan A. et al. Role of ultrasound and sonographically guided core biopsy in the diagnostic evaluation of ductal carcinoma in situ (DCIS) of the breast // Radiol. Med. 2007. — Vol.112 (6). -P.863−876.
- London S.J., Connolly J.L., Schnitt S.J. et al. A prospective study of benign breast disease and the risk of breast cancer // JAMA. 1992. — Vol.267 (7). -P.941−944.
- Lotan T.L., Ye H., Melamed J. et al. Immunohistochemical panel to identify the primary site of invasive micropapillary carcinoma // Am. J. Surg. Pathol. -2009.-Vol. 33 (7).-P.1037−1041.
- Lu D. Transcriptional regulation of the estrogen-inducible pS2 breast cancer marker gene by the ERR family of orphan nuclear receptors // Cancer Res.-2001.- Vol.61, № 18.- P.6755−6761.
- Ma XJ, Salunga R, Tuggle JT et al. Gene expression profiles of human breast cancer progression. Procl Natl Acad Sci USA 2003- 100: 5974−5979
- Macaluso M., Montanari M., Giordano A. The regulation of ER-alpha transcription by pRb2/pl30 in breast cancer // Ann. Oncol. 2005. — № 4. — P.20−22.
- MacGrogan G., Arnould L., De Mascarel I. et al. Impact of immunohistochemical markers, CK5/6 and E-cadherin on diagnostic agreement in non-invasive proliferative breast lesions // Histopathology. 2008. — Vol.52 (6). -P.689−697.
- Macaluso M., Montanari M., Giordano A. The regulation of ER-alpha transcription by pRb2/pl30 in breast cancer // Ann. Oncol.- 2005.- Vol. 4. P.20−22.
- Madjd Z., Durrant L.G., Bradley R. et al. Loss of CD55 is associated with aggressive breast tumors // Clin. Cancer Res. 2004. — Vol.15. — P.2797−803.
- Maglione J.E., Davis R.R., Baron C.A. et al. Heterogeneity of mammary lesions represent molecular differences // BMC Cancer. 2006. -Vol.5−6. -P.275.
- Maffiiz A., Barroso-Bravo S., Najera I. et al. Tumor size as predictor of microinvasion, invasion, and axillary metastasis in ductal carcinoma in situ // J. Exp. Clin. Cancer Res. 2006. — Vol.25 (2). — P.223−227.
- Manders P., Beex L.V., Tjan-Heijen V.C. et al. Vascular endothelial growth factor levels do not predict efficacy of systemic adjuvant treatment as assessed in 1127 breast cancer patients // Int. J. Oncol. 2004. — Vol.25 (2). -P.511−517.
- Marchio C., Iravani M., Natrajan R. et al. Mixed micropapillary-ductal carcinomas of the breast: a genomic and immunohistochemical analysis of morphologically distinct components // J. Pathol. 2009. — Vol.218 (3). — P.301−315.
- Marshall L.M., Hunter D.J., Connolly J.L. et al. Risk of breast cancer associated with atypical hyperplasia of lobular and ductal types // Cancer Epidemiol. Biomarkers Prev. 1997. — Vol.6 (5). — P.297−301.
- Mastracci T.L., Boulos F.I., Andrulis I.L., Lam W.L. Genomics and premalignant breast lesions: clues to the development and progression of lobular breast cancer // Breast Cancer Res. 2007. — Vol.9 (6). — P.215.
- Matros E. BRCA1 promoter methylation in sporadic breast tumors: relationship to gene expression profiles // Breast Cancer Res. Treat. 2005. -Vol.91, № 2. -P.179−186.
- Maxhimer J.B., Pesce C.E., Stewart R.A. et al. Ductal carcinoma in situ of the breast and heparanase-1 expression: a molecular explanation for more aggressive subtypes // J. Am. Coll. Surg. 2005. — Vol.200 (3). — P.328−335.
- McDivitt R.W., Stevens J.A., Lee N.C. et al. Histologic types of benign breast disease and the risk for breast cancer. The Cancer and Steroid Hormone Study Group // Cancer. 1992. — Vol.69 (6). — P.1408−1414.
- Medri L., Volpi A., Nanni O. et al. Prognostic relevance of mitotic activity in patients with node-negative breast cancer // Mod. Pathol. 2003. -Vol.16.-P.1067−1075.
- Mesurolle B., El-Khoury M., Khetani K. et al. Mammographically non-calcified ductal carcinoma in situ: sonographic features with pathological correlation in 35 patients // Clin. Radiol. 2009. — Vol.64 (6). — P.628−636.
- Michels J., Marnay J., Delozier T. et al. Proliferative activity in primary breast carcinomas is a salient prognostic factor // Cancer. 2004. -Vol.100.-P.455−464.
- Michels J.J., Duigou F., Marnay J. et al. Flow cytometry and quantitative immunohistochemical study of cell cycle regulation proteins in invasive breast carcinoma: prognostic significance // Cancer. 2003. — Vol.97. -P.1376−1386.
- Middleton L.P., Palacios D.M., Bryant B.R. et. al. Pleomorphic lobular carcinoma: morphology, immunohistichemistry, and molecular analysis // Am. J. Surg. Pathol. 2000. — Vol. 24. -P.1650−1656.
- Midulla C, Pisani T, De Iorio P, Cenci M, Divizia E, Nofroni I, Vecchione A: Cytological analysis and immunocytochemical expression of Ki67 and Bcl-2 in breast proliferative lesions. Anticancer Res 2002, 22:1341−1345.
- Moinfar F., Man Y.G., Arnould L. et al. Concurrent and independent genetic alterations in the stromal and epithelial cells of mammary carcinoma: implications for tumorigenesis // Cancer Res. 2000. — Vol.60 (9). — P.2562−2566.
- Molino A., Micciolo R., Turazza M. et al. Ki-67 immunostaining in 322 primary breast cancers: association with clinical and pathological variables and prognosis // Int. J. Cancer. 1997. — Vol.74. — P.433−437.
- Moll R., Mitze M., Frixen U.H., Birchmeier W. Differential loss of E-cadherin expression in infiltrating ductal and lobular breast carcinomas // Am. J. Pathol. 1993. — Vol. 143.-P.1731−1742.
- Montgomery R.B. Endogenous anti-HER2 antibodies block HER2 phosphorylation and signaling through extracellular signal-regulated kinase // Cancer Res. 2005.- Vol.65, № 2. — P.650−656.
- Monti S., Galimberti V., Trifiro G. et al. Occult breast lesion localization plus sentinel node biopsy (SNOLL): experience with 959 patients at the European Institute of Oncology // Ann. Surg. Oncol. 2007. — Vol.14 (10). -P.2928−2931.
- Moriya T., Hirakawa H., Suzuki T. et al. Ductal Carcinoma in situ and related lesions of the breast: recent advances in pathology practice // Breast Cancer. -2004.-Vol.ll (4).-P.325−333.
- Moriya T., Kozuka Y., Kanomata N. et al. The role of immunohistochemistry in the differential diagnosis of breast lesions // Pathology. -2009.-Vol.41 (1). -P.68−76.
- Mueller R.E., Parkes R.K., Andrulis I., O’Malley F.P. Amplification of the TOP2A gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samples // Genes Chromosomes Cancer. 2004. — Vol.39. -P. 288−297.
- Murphy L.C., Watson P. Steroid receptors in human breast tumorigenesis and breast cancer progression // Biomed. Pharmacother. 2002.-Vol.56, № 2. — P.65−77.
- Nagle R.B., Bocker W., Davis J.R. et al. Characterization of breast carcinomas by two monoclonal antibodies distinguishing myoepithelial fromluminal epithelial cells // J. Histochem. Cytochem. 1986. — Vol.34 (7). — P.869−881.
- Nass SJ, Herman JG, Gabrielson E, Iversen PW, Pari FF, Davidson NE, Graff JR: Aberrant methylation of the estrogen receptor and E-cadherin 5' CpG islands increases with malignant progresssion in human breast cancer. Cancer Res 2000, 60:4346−4348.
- Nayar R., Zhuang Z., Merino M.J., Silverberg S.G. Loss heterozygosity on chromosome llql3 in lobular lesions of the breast using tissue microdissection and polymerase chain reaction // Hum. Pathol. 1997. — Vol. 28. — P.277−282.
- Newman W. Lobular carcinoma of the female breast. Report of 73 cases//Ann. Surg. 1966.-Vol.164.-P. 305−314.
- Nielsen B.S., Rank F., Illemann M. et al. Stromal cells associated with early invasive foci in human mammary ductal carcinoma in situ coexpress urokinase and urokinase receptor // Int. J. Cancer. 2007. — Vol.120 (10). -P.2086−2095.
- Nofech-Mozes S., Holloway C., Hanna W. The role of cytokeratin 5/6 as an adjunct diagnostic tool in breast core needle biopsies // Int. J. Surg. Pathol. -2008.-Vol.16 (4). -P.399−406.
- Nunes R.A., Harris L.N. The HER2 extracellular domain as a prognostic and predictive factor in breast cancer // Clin. Breast Cancer.- 2002.-№ 2.- P.125−135.
- O’Connell P., Pekkel V., Fuqua S.A. et al. Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci // J. Natl. Cancer Inst. 1998. — Vol.90 (9). — P.697−703.
- Ohuchi N., Furuta A, Mori S. Management of ductal carcinoma in situ with nipple discharge. Intraductal spreading of carcinoma is an unfavorable pathologic factor for breast-conserving surgery // Cancer. 1994. — Vol.74 (4). -P.1294−1302.
- Ohuchi N. Breast-conserving surgery for invasive cancer: a principle based on segmental anatomy // Tohoku J. Exp. Med. 1999. -Vol.188 (2). -P.103−118.
- O’Malley F.P. et al. P53 mutations are confined to the comedo type ductal carcinoma in situ of the breast: immunohistochemical and sequencing data // Lab. Invest. 1994. — Vol.71. — P.67−72.
- Osako T., Takahashi K., Iwase T. et al. Diagnostic ultrasonography and mammography for invasive and noninvasive breast cancer in women aged 30 to 39 years // Breast Cancer. 2007. — Vol.14 (2). — P.229−233.
- Otterbach F., Bankfalvi A., Bergner S. et al. Cytokeratin 5/6 immunohistochemistry assists the differential diagnosis of atypical proliferations of the breast // Histopathology. 2000. -Vol.37 (3). — P.232−240.
- Ottesen G.L., Graversen H.P., Blichert-Toft M. et al. Carcinoma in situ of the female breast. 10 year follow-up results of a prospective nationwide study. // Breast Cancer Res. Treat. 2000. — Vol. 62. — P. 197−210.
- Ottesen G.L., Graversen H.P., Blichert-Toft M. et al. Lobular carcinoma in situ of the female breast. Short-term results of a prospective nationwide study. The Danish Breast Cancer Cooperative Group // Am. J. Surg. Pathol. -1993.-Vol.17.-P.14−21.
- Page D.L., Kidd T.E., Dupont W.D. et al. Lobular neoplasia of the breast: higher risk for subsequent invasive cancer predicted by more extensive disease //Hum. Pathol. 1991. — Vol. 22. — P. 1232−1239.
- Palli D., Rosselli del Turco M., Simoncini R. et al. Benign breast disease and breast cancer: a case-control study in a cohort in Italy // Int. J. Cancer. 1991.-Vol.47 (5). — P.703−706.
- Pallis L., Wilking N., Cedermark B. et. al. Receptors for estrogen and progesterone in breast carcinoma in situ // Anticancer Res. 1992. — Vol.12. — P. 2113−2115.
- Paredes J., Lopes N., Milanezi F., Schmitt F.C. P-cadherin and cytokeratin 5: useful adjunct markers to distinguish basal-like ductal carcinomas in situ // Virchows Arch. -2007.- Vol.450 (1).-P.73−80.
- Pavlakis K., Messini I., Vrekoussis T. et al. The assessment of angiogenesis and fibroblastic stromagenesis in hyperplastic and pre-invasive breast lesions // BMC Cancer. 2008. — Vol.88. — P. 1838−1848.
- Pearson G.W., Hunter T. Real-time imaging reveals that noninvasive mammary epithelial acini can contain motile cells // J. Cell Biol. 2007. -Vol.179 (7). -P.1555−1567.
- Perrone G., Altomare V., Zagami M. et al. Caveolin-1 expression in human breast lobular cancer progression // Mod. Pathol. 2009. — Vol.22 (1). -P.71−78.
- Perrone G., Zagami M., Altomare V. et al. COX-2 localization within plasma membrane caveolae-like structures in human lobular intraepithelial neoplasia of the breast// Virchows Arch. -2007.-Vol.451 (6). -P.1039−1045.
- Pope T.L., Fechner R.E., Wilhelm M.C. et al. Lobular carcinoma in situ of the breast: mammographic features // Radiology. 1988. — Vol.168. — P. 63−66.
- Pintens S., Neven P., Drijkoningen M. et al. Triple negative breast cancer: a study from the point of view of basal CK5/6 and HER-1 // J. Clin. Pathol. 2009. — Vol.62 (7). — P.624−628.
- Provenzano E, Hopper JL, Giles GG, Marr G, Venter DJ, Armes JE: Biological markers that predict clinical recurrence in ductal carcinoma in situ of the breast. Eur J Cancer 2003, 39:622−630.
- Rakha E.A. E-cadherin expression in invasive non-lobular carcinoma of the breast and its prognostic significance // Histopathology.- 2005.- Vol.46, № 6. P.685−693.
- Ramachandra S., Machin L., Ashley S. et. al. Immunohistochemical distribution of c-erbB-2 in in situ breast carcinoma: a detailed morphological analysis//J. Pathol. -I990.-Vol. 161.-P.7−14.
- Rasbridge S.A., Gillett C.E., Sampson S.A. et. al. Epithelial (E-) and placental (P-) Cadherin cell adhesion molecule expression in breast carcinoma // J. Pathol. 1993.-Vol.169.-P.245−250.
- Recht A., Rutgers E.J., Fentiman I.S. et al. The fourth EORTC DCIS Consensus meeting (Chateau Marquette, Heemskerk, The Netherlands, 23−24 January 1998)-conference report // Eur. J. Cancer. 1998. — Vol.34 (11). -P.1664−1669.
- Riener M.O., Nikolopoulos E., Herr A. et al. Microarray comparative genomic hybridization analysis of tubular breast carcinoma shows recurrent loss of the CDH13 locus on 16q // Hum. Pathol. 2008. — Vol. 39 (11). — P.1621−1629.
- Rohan TE, Hartwick W, Miller AB, Kandel RA: Immunohistochemical detection of c-erbB-2 and p53 in benign breast disease and breast cancer risk. J Natl Cancer Inst 1998, 90:1262−1269
- Rosen P.P., Braun D.W. Jr., Lyngholm B. et. al. Lobular carcinoma in situ of the breast: preliminary ressults of treatment by ipsilateral mastectomy and contralateral breast biopsy // Cancer. 1981. — Vol. 47. — P.813−819.
- Rosen P.P., Kosloff C., Lieberman P.H. et. al. Lobular carcinoma in situ of the breast. Detailed analysis of 99 patients with average follow-up of 24 years // Am. J. Surg. Pathol. 1978. — Vol. 2. — P. 225−251.
- Rosen P.P., Senie R., Schottenfeld D., Ashikari R. Noninvasive breast carcinoma: frequency of unsuspected invasion and implications for treatment // Ann. Surg. 1979. — Vol.189. -P.377−382.
- Rudas M., Neumayer R., Gnant M.F. et. al. P53 protein expression, cell proliferation and steroid hormone receptors in ductal and lobular in situ carcinomas of the breast // Eur. J. Cancer. 1997. — Vol. 33. — P. 39−44.
- Rushmere N.K., Knowlden J.M., Gee J.M. et al. Analysis of the level of mRNA expression of the membrane regulators of complement, CD59, CD55 and CD46, in breast cancer // Int. J. Cancer. 2004. — Vol. 108(6). — P.930−936.
- Saji S. et al. Expression of estrogen receptor (ER) (beta)cx protein in ER (alpha)-positive breast cancer: specific correlation with progesterone receptor // Cancer Res. 2002. — Vol.62, № 17.- P.4849−4853.
- Sakr R., Antoine M., Barranger E. et al. Value of sentinel lymph node biopsy in breast ductal carcinoma in situ upstaged to invasive carcinoma // Breast J. -2008.-Vol.14 (l).-P.55−60.
- Sapino A., Frigerio A., Peterse J.L. et.al. Mammographically detected in situ lobular carcinoma of the breast // Virchows Arch. 2000. — Vol. 436. — P. 421−430.
- Sartwell P.E., Arthes F.G., Tonascia J.A. Benign and malignant breast tumours: epidemiological similarities // Int. J. Epidemiol. 1978. — Vol.7 (3). -P.217−221.
- Schaefer F.K., Eden I., Schaefer P.J. et al. Factors associated with one step surgery in case of non-palpable breast cancer // Eur. J. Radiol. 2007. -Vol.64 (3). — P.426−431.
- Schmidt M., Khan A., Schmidt A.M. et al. A novel breast cancer cell line initially established from pleural effusion: evolution towards a more aggressive phenotype // Int. J. Oncol. 2007. -Vol.30 (3) -P.565−572.
- Schwarts G.F., Solin L.J., Olivotto I.A., Ernster V.L. The consensus conference on the treatment of in situ ductal carcinoma of the breast // The Breast J. 2000. — Vol. 6, № 1. — P. 4−13.
- Seethala R.R., Pasha T.L., Raghunath P.N. et al. The selective expression of CD43 in adenoid cystic carcinoma // Appl. Immunohistochem. Mol. Morphol. 2008. — Vol.16 (2). — P. 165−172.
- Shakney SE, Silverman JF. Molecular evolutionary patterns in breast cancer. Adv Anat Pathol 2003- 10: 278−290- Simpson PT, Reis-Filho JS, Gale T, Lakhani SR. Molecular evolution of breast cancer. J Pathol2005- 248−254
- Shaye A., Sahin A., Hao Q. et al. Cyclin E deregulation is an early event in the development of breast cancer // Breast Cancer Res. Treat. 2009. -Vol.115 (3).-P.651−659.
- Shoker B.S., Jarvis C., Sibson D.R. et al. Oestrogen receptor expression in the normal and pre-cancerous breast // Pathol. 1999. — Vol.188 (3). -P.23 7−244.
- Silver S.A., Tavassoli F.A. Pleomorphic carcinoma of the breast: clinicopathological analysis of 28 cases of an unusual high-grade phenotype of ductal carcinoma // Histopathology. 2000. — Vol. 36. — P.505−514.
- Silverstein M.J., Lagios M.D., Craig P.H. et al. A prognostic index for ductal carcinoma in situ of the breast // Cancer (Philad.). 1996. — Vol. 77. — P. 1167−1174.
- Simpson P.T., Gale T., Reis-Filho J.S. et al. Columnar cell lesions of the breast: the missing link in breast cancer progression? A morphological and molecular analysis // Am. J. Surg. Pathol. 2005. — Vol.29 (6). — P.734−746.
- Simpson P.T., Reis-Filho J.S., Lambros M.B. et al. Molecular profiling pleomorphic lobular carcinomas of the breast: evidence for a common molecular genetic pathway with classic lobular carcinomas // J. Pathol. 2008. -Vol.215 (3).-P.231−244.
- Span P.N., Tjan-Heijnen V.C., Manders P. et al. Cyclin-E is a strong predictor of endocrine therapy failure in human breast cancer // Oncogene. 2003. — Vol.22. -P.4898−4904.
- Stomper P.C., Connolly J.L. Ductal carcinoma in situ of the breast: correlation between mammographic calcification and tumor subtype // AJR Am. J. Roentgenol. 1992.- Vol.159 (3). -P.483−485.
- Sun J.M., Han W., Kim D.W. et al. Clinical relevance of Her-2 expression in node-negative breast cancer patients // Proc. Am. Soc. Clin. Oncol. -2004.-Vol.23.
- Sutherland R.L., Musgrove E.A. Cyclins and breast cancer // J. Mammary Gland Biol. Neoplasia. 2004. — Vol.9. — P. 95−104.
- Sydnor M.K., Wilson J.D., Hijaz T.A. et al. Underestimation of the presence of breast carcinoma in papillary lesions initially diagnosed at core-needle biopsy // Radiology. 2007. — Vol.242 (1). — P.58−62.
- Tang P, Hajdu SI, Lyman GH. Ductal carcinoma in situ: a review of recent advances. Curr Opin Obstet Gynecol 2007- 19:63−67
- Tamimi R.M., Baer HJ., Marotti J. et al. Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer // Breast Cancer Res. -2008.-Vol.10 (4).-P.67.
- Tavassoli F.A. Lobular neoplasia (lobular carcinoma in situ). En Pathology of the breast. // Appleton&Lange, Norwalk, 1992. p. 263−91.
- Tavassoli F.A., Millis R.R., Boecker W., Lakhani S.R. Lobular neoplasia // WHO classflcation of tumours. Patology and Genetics of tumours of the breast and female genital organs. IARC-Press. Lyon, 2003. — P.60−62.
- Tavassoli F.A., Norris H.J. A comparison of the results of long-term follow-up for atypical intraductal hyperplasia and intraductal hyperplasia of the breast // Cancer. 1990. — Vol.65 (3). — P.518−529.
- Tavassoli F.A., Norris H.J. Intraductal apocrine carcinoma: a clinicopathologic study of 37 cases // Mod. Pathol. 1994. — Vol.7 (8). — P.813−818.
- Thor A.D., Liu S., Moore D.H. et al. p (21WAFl/CIPl) expression in breast cancers: associations with p53 and outcome // Breast Cancer Res. Treat. -2000.-Vol.61.-P.33−43.
- Thor A.D. et al. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers // J. Natl. Cancer Inst. -1992.- Vol.84.-P.845−855.
- Trihia H., Murray S., Price K. et al. Ki-67 expression in breast carcinoma: its association with grading systems, clinical parameters, and other prognostic factors-a surrogate marker? // Cancer. 2003. — Vol. 97. — P. 13 211 331.
- Tsanou E. Clinicopathological study of the expression of syndecan-1 in invasive breast carcinomas. Correlation with extracellular matrix components // J. Exp. Clin. Cancer Res. 2004. — Vol.23, № 4. — P.641−650.
- Tse G.M., Tan P.H., Moriya T. The role of immunohistochemistry in the differential diagnosis of papillary lesions of the breast // J. Clin. Pathol. -2009. Vol.62 (5). -P.407−413.
- Tunon-de-Lara C., Giard S., Buttarelli M. et al. Sentinel node procedure is warranted in ductal carcinoma in situ with high risk of occult invasive carcinoma and microinvasive carcinoma treated by mastectomy // Breast J. -2008. Vol.14 (2). -P.135−140.
- Turashvili G., Hayes M., Gilks B. et al. Are columnar cell lesions the earliest histologically detectable non-obligate precursor of breast cancer? // Virchows Arch. 2008. — Vol.452 (6). — P.589−598.
- Umekita Y, Yoshida H. Cyclin D1 expression in ductal carcinoma in situ, atypical ductal hyperplasia and usual ductal hyperplasia: An immunohistochemical study. Pathol Int 2000- 50: 527−530
- Ursini-Siegel J., Muller W.J. The ShcA adaptor protein is a critical regulator of breast cancer progression // Cell Cycle. 2008. — Vol.7 (13). -P.1936−1943.
- Van der Groep P., Van Diest P.J., Menko F.H. et al. Molecular profile of ductal carcinoma in situ of the breast in BRCA1 and BRCA2 germline mutation carriers // J. Clin. Pathol. 2009. — Vol.62 (10). — P.926−930.
- Van Diest P.J., Van der Wall E., Baak J.P. Prognostic value of proliferation in invasive breast cancer: a review // J. Clin. Pathol. 2004. — Vol.57. -P.675−681.
- Viacava P, Naccarato AG, Bevilacqua G: Different proliferative patterns characterize different preinvasive breast lesions. JPathol 1999, 188:245 251
- Vos C.B., Cleton-Jansen A.M., Berx G. et. al. E-cadherin inactivation in lobular carcinoma in situ of the breast: an early event in tumorigenesis // Br. J. Cancer. 1997. — Vol. 76.-P. 1131−1133.
- Wagner P.L., Kitabayashi N., Chen Y.T., Shin S.J. Clonal relationship between closely approximated low-grade ductal and lobular lesions in the breast: a molecular study of 10 cases // Am. J. Clin. Pathol. 2009. — Vol.132 (6). — P.871−876.
- Wang L.H. et al. Relationship between lymph node metastasis and the expressions of E-cadherin, N-cadherin, and matrix metalloproteinase in breast carcinoma // Ai Zheng. 2002. — Vol.21, № 9. — P.965−969.
- Ward B.A., McKhann C.F., Ravikumar T.S. Ten-year follow-up of breast carcinoma in situ in Connecticut // Arch. Surg. 1992. — Vol.127 (12). -P.1392−1395.
- Webster L.R., Lee S.F., Ringland C. et al. Poor-prognosis estrogen receptor-positive breast cancer identified by histopathologic subclassification // Clin Cancer Res. 2008. — Vol.14 (20). — P.6625−6633.
- Wellings S.R., Jensen H.M., Marcum R.G. An atlas of subgross pathology of the human breast with special reference to possible precancerous lesions // J. Natl. Cancer Inst. 1975. — Vol. 55. — P.231−273.
- Wells W.A., Wang X., Daghlian C.P. et al. Phase contrast microscopy analysis of breast tissue: differences in benign vs. malignant epithelium and stroma // Anal Quant Cytol. Histol. 2009. — Vol.31 (4). — P. 197−207.
- Werner M., Mattis A., Aubele M. et al. 20ql3.2 amplification in intraductal hyperplasia adjacent to in situ and invasive ductal carcinoma of the breast // Virchows Arch. 1999. — Vol.435 (5). — P.469−472.
- Wheeler J.E., Enterline H.T. Lobular carcinoma of the breast in situ and infiltrating//Pathol. Annu. 1976. — Vol.11. -P.161−188.
- Wingate H., Bedrosian I., Akli S., Keyomarsi K. The low molecular weight (LMW) isoforms of cyclin E deregulate the cell cycle of mammary epithelial cells // Cell Cycle. 2003. — Vol. 2. — P.461−466.
- Yamaguchi R., Tanaka M., Kishimoto Y. et al. Ductal carcinoma in situ arising in a benign phyllodes tumor: report of a case // Surg. Today. — 2008. -Vol.38 (l).-P.42−45.
- Yamaguchi R., Tanaka M., Otsuka H. et al. Neuroendocrine small cell carcinoma of the breast: report of a case // Med. Mol. Morphol. 2009. — Vol.42 (1). — P.58−61.
- Yi M., Krishnamurthy S., Kuerer H.M. et al. Role of primary tumor characteristics in predicting positive sentinel lymph nodes in patients with ductal carcinoma in situ or microinvasive breast cancer // Am. J. Surg. 2008. — Vol.196 (1). -P.81−87.
- Younes M, Lebovitz RM, Bommer KE, Cagle PT, Morton D, Khan S, Laucirica R: p53 accumulation in benign breast biopsy specimens. Hum Pathol 1995, 26:155−158
- Zagouri F., Sergentanis T.N., Zografos G.C. Precursors and preinvasive lesions of the breast: the role of molecular prognostic markers in the diagnostic and therapeutic dilemma // World J. Surg. Oncol. 2007. — Vol.31 (5). -P.57.
- Zavagno G., Belardinelli V., Marconato R. et al. Sentinel lymph node metastasis from mammary ductal carcinoma in situ with microinvasion // Breast. 2007. — Vol.16 (2). — P. 146−151.
- Zhao X., Goswami M., Pokhriyal N. et al. Cyclooxygenase-2 expression during immortalization and breast cancer progression // Cancer Res. -2008. Vol.68 (2). — P.467−475.
- Zhou Ch, Zhang Q, Zhang T et al. Expression of ER, Ki-67 and CylinDl in the Pre-cancerous Breast of Chinese Patients. Pathol. Oncol. Res. (2009) 15:153−158
- Zhu X.L., Hartwick W., Rohan T. et al. Cyclin D1 gene amplification and protein expression in benign breast disease and breast carcinoma // Mod. Pathol. 1998.-Vol.11 (11).-P. 1082−1088.
- Zou D., Yoon H.S., Anjomshoaa A. et al. Increased levels of active c-Src distinguish invasive from in situ lobular lesions // Breast Cancer Res. 2009. -Vol.11(4).-P.45.